gefitinib has been researched along with celastrol in 3 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (celastrol) | Trials (celastrol) | Recent Studies (post-2010) (celastrol) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 885 | 1 | 741 |
| Protein | Taxonomy | gefitinib (IC50) | celastrol (IC50) |
|---|---|---|---|
| Telomerase reverse transcriptase | Homo sapiens (human) | 0.78 | |
| Ubiquitin carboxyl-terminal hydrolase 2 | Homo sapiens (human) | 6.8 | |
| Ubiquitin carboxyl-terminal hydrolase isozyme L1 | Homo sapiens (human) | 6.8 | |
| Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) | 8.41 | |
| Ubiquitin carboxyl-terminal hydrolase isozyme L3 | Homo sapiens (human) | 6.8 | |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | 3.45 | |
| Tyrosine-protein phosphatase non-receptor type 6 | Homo sapiens (human) | 3.1 | |
| Tyrosine-protein phosphatase non-receptor type 11 | Homo sapiens (human) | 3.5667 | |
| Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | 0.25 | |
| Regulator of G-protein signaling 17 | Homo sapiens (human) | 6.1795 | |
| Ubiquitin carboxyl-terminal hydrolase 15 | Homo sapiens (human) | 6.8 | |
| Ubiquitin carboxyl-terminal hydrolase isozyme L5 | Homo sapiens (human) | 6.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, XX; He, JX; Leung, EL; Li, N; Liu, L; Wu, JL; Zhou, YL | 1 |
| Coghi, PS; Fan, XX; Law, BY; Leung, CH; Leung, EL; Liu, L; Ma, DL; Mok, SW; Wong, VK; Xu, SW; Zeng, W | 1 |
| Kim, SY; Lee, C; Lee, YJ | 1 |
3 other study(ies) available for gefitinib and celastrol
| Article | Year |
|---|---|
Celastrol induces apoptosis in gefitinib-resistant non-small cell lung cancer cells via caspases-dependent pathways and Hsp90 client protein degradation.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mitochondria; Pentacyclic Triterpenes; Protein Kinase Inhibitors; Proteolysis; Quinazolines; Signal Transduction; Triterpenes | 2014 |
Autophagic degradation of epidermal growth factor receptor in gefitinib-resistant lung cancer by celastrol.
Topics: Antineoplastic Agents; Autophagy; Blotting, Western; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Pentacyclic Triterpenes; Proteolysis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Triterpenes; Tumor Cells, Cultured | 2016 |
Axl is a novel target of celastrol that inhibits cell proliferation and migration, and increases the cytotoxicity of gefitinib in EGFR mutant non‑small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression; Humans; Lung Neoplasms; Mutation; Pentacyclic Triterpenes; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Triterpenes | 2019 |